close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theriva Biologics, Inc. Common Stock (NY:TOVX)

0.2506 +0.0132 (+5.56%)
Official Closing Price Updated: 4:10 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theriva Biologics, Inc. Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Theriva Biologics? ↗
 
Via Benzinga
News headline image
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Peering Into Theriva Biologics's Recent Short Interest ↗
 
Via Benzinga
News headline image
What's Going On With Theriva Biologics (TOVX) Stock? ↗
Theriva Biologics shares are trading lower by 8.4% Monday morning. The company announced a 1-for-25 reverse stock split. 
Via Benzinga
News headline image
Preview: Theriva Biologics's Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
What's Going On With Theriva Biologics Stock? ↗
Theriva Biologics shares are trading higher Friday on continued momentum following a series of catalysts this week. Here's a look at the details: 
Via Benzinga
News headline image
Nasdaq Jumps Over 100 Points; Dell Posts Upbeat Results ↗
 
Via Benzinga
News headline image
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma
Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma 
Via News Direct
News headline image
Nasdaq Surges 150 Points; Sonder Holdings Shares Surge ↗
 
Via Benzinga
News headline image
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher ↗
 
Via Benzinga
News headline image
Dow Jumps Over 100 Points; Estee Lauder Shares Edge Lower After Q4 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
TOVX Stock Earnings: Theriva Biologics Beats EPS for Q2 2024 ↗
TOVX stock results show that Theriva Biologics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers
Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers 
Via News Direct
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer
--News Direct-- 
Via News Direct
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
TOVX Stock Earnings: Theriva Biologics Beats EPS for Q1 2024 ↗
TOVX stock results show that Theriva Biologics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers
Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers 
Via News Direct
News headline image
Earnings Scheduled For March 25, 2024 ↗
Companies Reporting Before The Bell • Bitcoin Depot (NASDAQ:BTM) is expected to report quarterly loss at $0.08 per share on revenue of $161.50 million. 
Via Benzinga
How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need
--News Direct-- 
Via News Direct
Topics Death
Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology
--News Direct-- 
Via News Direct
For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers
--News Direct-- 
Via News Direct
Topics Death
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today